Replies to post #10326 on Loss to Profit, let's make your lost money back !

[IPRE-Paramount]

The last contract was to aim development of a generic drug to be ready go on sales for 2015. This little co has some other develppments.

But let's treat it as a biopharm, meaning terribly volatile.Buy it if you consider it's a mega cheap stock.

About pure biotech, you know 5-6 years ago, i made a +60% on OXGN when it popped to $10 because they got funded by another seriious company to develop their product. Since then, looks like there was no real bad news, it was just like Capital erosion year after year and we have now OXGN at 25c !

But a biopharm in the generic drugs looks to me less risky than a pure biotech with all its damm difficults phase I-II-III.